Gene Therapy Trial for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

a study on Retinitis Pigmentosa

Summary

Eligibility
for people ages 3 years and up (full criteria)
Location
at San Diego, California and other locations
Dates
study started
estimated completion

Description

Summary

A clinical trial of AAV5-RPGR vector for patients with X-linked retinitis pigmentosa (XLRP)

Official Title

Phase 3 Randomized, Controlled Study of AAV5-RPGR for the Treatment of X-linked Retinitis Pigmentosa Associated With Variants in the RPGR Gene

Details

Deferred Treatment

Keywords

X-Linked Retinitis Pigmentosa, Retinitis, Retinitis Pigmentosa, Genetic: AAV5-RPGR

Eligibility

You can join if…

Open to people ages 3 years and up

  • Male or female
  • 3 years of age or older
  • has XLRP confirmed by a retinal specialist and has a predicted disease-causing sequence variant in RPGR confirmed by an accredited laboratory.

You CAN'T join if...

Locations

  • Shiley Eye Institute, University of California San Diego accepting new patients
    San Diego California 92093-0946 United States
  • Children's Hospital Los Angeles accepting new patients
    Los Angeles California 90027 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
MeiraGTx UK II Ltd
ID
NCT04671433
Phase
Phase 3 Retinitis Pigmentosa Research Study
Study Type
Interventional
Participants
Expecting 96 study participants
Last Updated
Contact us about this trial